Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers

Ji Soo Choi1,*, Dahye Yoon2,*, Ja Seung Koo3, Siwon Kim4, Vivian Youngjean Park5, Eun-Kyung Kim5, Suhkmann Kim2 and Min Jung Kim5

1Department of Radiology, Breast Cancer Center, Samsung Medical Center, Seoul, Korea
2Department of Chemistry, Center for Proteome Biophysics and Chemistry Institute for Functional Materials, Pusan National University, Busan, Korea
3Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
4Department of Forensic Chemistry, National Forensic Service Busan Institute, Yangsan-si, Korea
5Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea

*These authors have contributed equally to this work

Correspondence to: Min Jung Kim, email: mines@yuhs.ac
Suhkmann Kim, email: suhkmann@pusan.ac.kr

Keywords: breast cancer, ER-positive, luminal, HR-MAS MRS (high-resolution magic angle spinning magnetic resonance spectroscopy), biomarker

Received: January 10, 2017 Accepted: June 02, 2017 Published: June 28, 2017

ABSTRACT

Estrogen receptor (ER)-positive breast cancers overall have a good prognosis, however, some patients suffer relapses and do not respond to endocrine therapy. The purpose of this study was to determine whether there are any correlations between high-resolution magic angle spinning (HR-MAS) magnetic resonance spectroscopy (MRS) metabolic profiles of core needle biopsy (CNB) specimens and the molecular markers currently used in patients with ER-positive breast cancers. The metabolic profiling of CNB samples from 62 ER-positive cancers was performed by HR-MAS MRS. Metabolic profiles were compared according to human epidermal growth factor receptor 2 (HER2) and Ki-67 status, and luminal type, using the Mann-Whitney test. Multivariate analysis was performed with orthogonal projections to latent structure-discriminant analysis (OPLS-DA). In univariate analysis, the HER2-positive group was shown to have higher levels of glycine and glutamate, compared to the HER2-negative group ($P<0.01$, and $P<0.01$, respectively). The high Ki-67 group showed higher levels of glutamate than the low Ki-67 group without statistical significance. Luminal B cancers showed higher levels of glycine ($P=0.01$) than luminal A cancers. In multivariate analysis, the OPLS-DA models built with HR-MAS MR metabolic profiles showed visible discrimination between the subgroups according to HER2 and Ki-67 status, and luminal type. This study showed that the metabolic profiles of CNB samples assessed by HR-MAS MRS can be used to detect potential prognostic biomarkers as well as to understand the difference in metabolic mechanism among subtypes of ER-positive breast cancer.

INTRODUCTION

Since it became known that a large subset of breast cancers depends on estrogen receptor (ER) signaling, leading to the clinical application of endocrine therapies (e.g., tamoxifen, aromatase inhibitors), breast cancers have been classified into ER-positive and ER-negative cancers [1–5]. With appropriate endocrine therapy, patients with ER-positive cancers have significantly better outcomes than those with ER-negative cancers [1–4]. Subsequent
gene expression profiling studies of ER-positive breast cancers demonstrated that this group is still heterogeneous in ER expression levels and proliferation-related genes [6, 7], which is associated with clinical outcomes and treatment response. Currently, ER-positive cancers are subclassified into luminal A and luminal B types based on human epidermal growth factor receptor 2 (HER2) overexpression and Ki-67 labeling index using a cutoff of 14% [8]. Luminal B cancers, high proliferative ER-positive cancers, have a poor prognosis compared to luminal A [9, 10]. This “intrinsic gene” molecular subclassification of ER-positive cancers has been widely used by clinicians to predict prognosis and to select treatment options for patients with these cancers [8, 11].

In addition to the genetic alteration of cancer, metabolic alteration of cancer is also important to understand the cancer biology and to find potential biomarkers that can be targeted therapeutically [12, 13]. Metabolic alterations are the consequence of genetic alterations in metabolic pathways and are directly linked to cell phenotype [14]. Accordingly, the metabolite levels of the cells provide functional changes associated with cell metabolism [12, 15, 16]. Metabolomics is defined as the study of all of the metabolites of a cell, tissue or organism for a comprehensive understanding of metabolism [12, 14, 16, 17]. Recent metabolomic studies have shown that ex vivo high-resolution magic angle spinning magnetic resonance spectroscopy (HR-MAS MRS) can be used for the identification and quantification of numerous metabolites in a tissue sample [12, 16, 18–23]. Compared to other metabolomic approaches, HR-MAS MRS requires less sample treatment and does not damage tissue integrity after the experiment, thus allowing reuse of the tissue sample for other diagnostic examinations. In HR-MAS MRS studies using human breast tissue, surgical specimens or core needle biopsy (CNB) specimens were used [18–23]. Metabolic profiles of CNB samples are applicable to preoperative decision-making for the best treatment approach for breast cancer patients, whereas metabolic profiles of surgical samples are not. Previous HR-MAS MRS studies using CNB samples have reported that metabolic profiles of CNB samples may be helpful in the diagnosis and characterization of breast cancer, and monitoring of responses to neoadjuvant chemotherapy in locally advanced breast cancer [20, 21, 24].

Profiling intrinsic gene expression and metabolite content in the same breast cancer tissue could reveal differences and similarities in the metabolic composition between groups of samples at different gene expression levels and provide increased insight into functional changes that are potential targets for pharmacological or nutritional intervention [25]. Although recent studies have compared metabolic profiles between triple-negative breast cancers and ER-positive breast cancers [18, 26], no HR-MAS MRS studies, to our knowledge, have examined the association between metabolic and molecular markers only in ER-positive breast cancers. The comparison between metabolic profiles and expression levels of HER2 and Ki-67, which are used in molecular classification of ER-positive breast cancer tissue, may help identify potential biomarkers associated with clinically aggressive subgroups. Therefore, the purpose of this study was to determine whether there are any correlations between HR-MAS MRS metabolic profiles of CNB specimens and molecular markers currently used in patients with ER-positive breast cancers.

RESULTS

The median age of the study population was 51.5 years (range, 32-84 years; interquartile range [IQR], 45-60 years). The median tumor size was 1.6 cm (range, 0.5-4.2 cm; IQR, 1.2-2.2 cm). The most common histologic type of ER-positive cancers was invasive ductal carcinoma (n=57) and other cancers included three mucinous carcinomas and two invasive lobular carcinomas.

All study patients received proper management after surgery and underwent postoperative surveillance with US or mammography after initial treatment. The follow-up period ranged from 35-72 months (median, 42 months; interquartile range, 39.5-68 months). None of the patients had a breast cancer recurrence during the follow-up period.

As shown in Table 1, relative quantification showed that several metabolite levels of CNB tissue samples were significantly different between the groups. The HER2-positive group was characterized by higher levels of Gly and Glu, compared to the HER2-negative group (P<0.01 and P<0.01 respectively). The HER2-positive group showed higher level of Cho, without reaching statistical significance (P=0.04). The high Ki-67 group showed higher level of Glu than the low Ki-67 group, with borderline significance (P=0.02). Luminal B cancers showed significantly higher levels of Gly (P =0.01) than luminal A cancers (Figure 1). Luminal B cancers showed higher levels of PC and Tau (P=0.03, and P =0.05, respectively) and lower levels of Ile (P=0.04) than luminal A cancers (Figure 1), although the differences did not reach statistical significance.

For multivariate analysis, OPLS-DA separation models were produced with the HR-MAS MRS data according to HER2 and Ki-67 status, and luminal type. The OPLS-DA models showed visible discrimination between the groups, although some samples crossed over the reference line (Figure 2). Corresponding OPLS-DA loading S plots showed that Gly, PC, Cho, and Tau were contributing metabolites for prediction of the groups of ER-positive cancers. In addition, Leu contributed to discrimination of HER2-negative, low Ki-67, and luminal A groups from corresponding groups, although the level of Leu showed no statistical significance in univariate analysis. OPLS-DA prediction models of this study showed high sensitivities with a range of 94.4-100% for prediction of HER2, Ki-67, and luminal type (Table 2).
Table 1: Comparison between the relative metabolite quantification levels of ER-positive breast cancers according to the tumor groups

| Metabolite | HER2 Negative (n=52) | HER2 Positive (n=10) | P | Ki-67 Low (n=39) | Ki-67 High (n=23) | P | Molecular subtype* |
|------------|----------------------|---------------------|---|----------------|------------------|---|-------------------|
| Cho        | 1.16 (0.88-1.71)     | 1.74 (1.34-2.05)    | 0.04 | 1.33 (0.85-1.74) | 1.32 (1.00-1.79) | 0.60 | 1.30 (0.83-1.71) | 1.48 (1.00-1.92) | 0.07 |
| PC         | 1.15 (0.69-1.49)     | 1.51 (1.35-1.75)    | 0.08 | 1.09 (0.67-1.59) | 1.41 (1.18-1.58) | 0.27 | 1.08 (0.58-1.43) | 1.41 (1.18-1.62) | 0.03 |
| GPC        | 0.46 (0.35-0.70)     | 0.43 (0.30-0.57)    | 0.14 | 0.46 (0.29-0.71) | 0.47 (0.36-0.56) | 0.48 | 0.46 (0.30-0.70) | 0.45 (0.36-0.57) | 0.42 |
| Gly        | 4.97 (5.28-8.71)     | 9.60 (8.51-9.93)    | <0.01 | 7.05 (5.14-8.86) | 8.54 (6.47-9.68) | 0.15 | 6.89 (5.02-8.63) | 8.56 (6.51-9.69) | 0.01 |
| Ser        | 5.57 (4.35-6.79)     | 5.90 (5.40-6.42)    | 0.30 | 5.60 (4.04-6.86) | 5.75 (4.66-6.46) | 0.32 | 5.52 (4.11-6.79) | 5.81 (4.65-6.49) | 0.67 |
| Tau        | 4.91 (2.92-6.07)     | 5.87 (5.36-6.45)    | 0.10 | 4.96 (2.87-6.08) | 5.71 (3.99-6.52) | 0.77 | 4.91 (2.77-5.99) | 5.75 (4.11-6.95) | 0.05 |
| Leu        | 3.51 (3.03-4.06)     | 3.36 (2.98-4.34)    | 0.86 | 3.51 (3.04-7.03) | 3.41 (2.89-4.33) | 0.79 | 3.58 (3.13-4.06) | 3.38 (2.87-4.30) | 0.39 |
| Ile        | 1.65 (1.41-2.10)     | 1.46 (1.29-1.76)    | 0.10 | 1.66 (1.42-2.30) | 1.56 (1.36-1.79) | 0.20 | 1.68 (1.43-2.34) | 1.57 (1.36-1.76) | 0.04 |
| Gln        | 1.90 (1.47-2.24)     | 2.02 (1.40-2.39)    | 0.35 | 1.98 (1.43-2.25) | 1.93 (1.42-2.36) | 0.98 | 2.04 (1.60-2.26) | 1.89 (1.35-2.33) | 0.33 |
| Glu        | 6.18 (5.03-6.78)     | 7.46 (6.30-9.15)    | <0.01 | 6.07 (4.82-6.73) | 6.64 (5.93-8.25) | 0.02 | 6.13 (4.97-6.77) | 6.55 (5.88-8.24) | 0.19 |
| Cr         | 1.17 (0.82-1.77)     | 1.13 (0.74-1.49)    | 0.34 | 1.16 (0.75-1.83) | 1.17 (0.87-1.72) | 0.32 | 1.12 (0.72-1.80) | 1.17 (0.91-1.74) | 0.78 |
| m-Ins      | 1.79 (1.43-2.61)     | 2.44 (2.09-2.89)    | 0.05 | 2.10 (1.43-2.67) | 2.03 (1.55-2.55) | 0.87 | 2.08 (1.42-2.80) | 2.05 (1.54-2.57) | 0.51 |
| Ala        | 5.52 (4.44-6.64)     | 6.78 (5.74-7.82)    | 0.17 | 5.50 (4.40-6.72) | 6.23 (5.02-6.96) | 0.80 | 5.46 (4.45-6.37) | 6.26 (4.91-7.21) | 0.11 |

Cho: choline; PC: phosphocholine; GPC: glycerylphosphocholine; Gly: glycine; Ser: serine; Tau: taurine; Gly: glycine; Leu: leucine; Ile: isoleucine; Gln: glutamine; Glu: glutamate; Cr: creatine; m-Ins: myo-inositol; Ala: alanine.

*St Gallen surrogate molecular subtype.

IQR: interquartile range.

Bold indicates statistical significance (P<0.0167).

DISCUSSION

Patients with ER-positive breast cancers are generally thought to have a good prognosis, but some experience recurrence while others have cancers that are unresponsive to endocrine therapy [8, 25]. Metabolic profiling of ER-positive cancers may help to detect biomarkers that can be used to identify aggressive subgroups. Recent studies have performed metabolic profiling of ER-positive breast cancers using surgically obtained tissue [18, 25–27]. However, metabolic profiles of surgical samples cannot be obtained preoperatively for planning of therapeutic strategies. On the other hand, metabolic profiles of cancer samples obtained by US-guided CNB, standard procedure for preoperative diagnosis of breast cancers [28], are applicable to preoperative decision-making for the best treatment approach. In addition, several studies have reported that some protein and phosphoprotein levels were significantly higher in CNB compared with surgical samples suggesting a potential degradation of phosphorylation during surgical manipulation, or with cold ischemia of surgical samples [29, 30]. We have previously investigated HR-MAS MRS data of CNB breast cancer samples, and the results showed that several metabolites were found to correlate with IHC status of tumor [20]. In that study, ER-negative cancers showed significantly higher levels of Cho than ER-positive cancers. However, the study population of this past study included only 28 cases of ER-positive cancers, and we did not perform subgroup analysis according to molecular subtype. Considering that ER-positive cancers make up approximately 70% of breast cancers and that treatment outcomes differ according to molecular subtype (luminal A vs. B) [31], we attempted to conduct HR-MAS MRS metabolic profiling with a larger number CNB samples of ER-positive cancers in this study.

HER2 overexpression is associated with more aggressive disease and poorer prognosis compared to HER2 negativity [32]. Patients with HER2-positive cancers have been shown to be effectively treated by HER2-targeted therapy (e.g., trastuzumab) [33]. Accordingly, HER2 status evaluation is currently used to classify ER-positive cancers into luminal A or B type to guide therapeutic strategies. In this study aimed at ER-positive breast cancers, the HER2-positive group and luminal B group showed significantly higher levels of Gly compared to the HER2-negative group and luminal A group, respectively. This is in accordance with a recent study in which there was a positive association between Gly level in surgical specimens and HER2-positive cancers [18]. Gly is an amino acid involved in the synthesis of proteins, nucleotides and glutathione, and higher levels of Gly have previously been found to correlate with rapid cell proliferation and poor prognosis in breast cancer [22, 27, 34]. In addition, a recent study reported that glycine decarboxylase (GLDC), which is...
Figure 1: The HR-MAS MR spectra (11.7T) obtained using core needle biopsy specimens show the peaks of each metabolite. (A) A 48-year-old woman with luminal B type ER-positive invasive ductal carcinoma (tumor size 17 mm, presence of lymph node metastasis, HER2-positive, High Ki-67). (B) A 57-year-old woman with luminal A type ER-positive invasive ductal carcinoma (tumor size 15 mm, no lymph node metastasis, HER2-negative, Low Ki-67).

Gly, glycine (3.55 ppm, singlet); Tau, taurine (3.24 and 3.41 ppm, triplet); GPC, glycerophosphocholine (3.22 ppm, singlet); PC, phosphocholine (3.21 ppm, singlet); Cho, free choline (3.20 ppm, singlet); Cr, creatine (3.03 ppm, singlet); Lys, lysine (3.01 triplet/1.72 and 1.89 ppm, multiplet); Gln, glutamine (2.15 and 2.44 ppm, multiplet); Glu, glutamate (2.08 and 2.34 ppm, multiplet); Leu, leucine (1.69 ppm multiplet/0.91 and 0.94 ppm, doublet); Ala, alanine (1.47 ppm, doublet); Val, valine (0.98 and 1.04 ppm, doublet); Ile, isoleucine (0.99 ppm, triplet/1.02 ppm doublet).
Figure 2: OPLS-DA score and loading S-plots of the HR-MAS MRS spectra for HER2, Ki-67 status, and luminal type. (A) HER2-positive vs. HER2-negative, (B) high Ki-67 vs. low Ki-67, and (C) luminal A vs. luminal B.
associated with Gly metabolism, was highly expressed in HER2-positive cancers [35]. Although the precise mechanism of increased GLDC in HER2-positive cancers is unknown, a 20-fold increase in GLDC expression was seen in MCF10A cells after oncogenic transformation by KRAS<sup>G12D</sup>, PIK3CA<sup>E545K</sup>, or MYC<sup>CT88A</sup> [36], suggesting that HER2-positive cancer may be driven by certain HER2 oncogenes. Therefore, based on results from previous studies combined with our results, we suggest that Gly may have potential as a prognostic biomarker that reflects tumor aggressiveness associated with HER2 overexpression in ER-positive cancers as well as HER2-positive subtype of breast cancer.

Along with HER2-positivity, a high Ki-67 proliferation index is associated with worse survival outcome in breast cancer patients [37]. Our high Ki-67 and HER2-positive aggressive subgroups of ER-positive cancer showed significantly higher levels of Glu compared to the corresponding groups, although Gln levels were not significantly different. Gln provides nitrogen for protein and nucleotide synthesis and Gln addiction has been described as a main feature of cancer cell metabolism [38]. Our findings may reflect an early step in increased glutaminolysis in which Gln is converted to Glu in the cytosol or mitochondria [38]. This finding is in accordance with a recent study in which Glu enrichment was found in 56% of ER-positive cancers and in 88% of ER-negative cancers, compared with normal breast tissue. Other recent studies have reported increased glutaminolysis to be more prominent in ER-negative or triple negative cancers compared to ER-positive cancers [18, 39]. Along with previous studies, our results indicate that targeting the metabolites or enzymes related to glutaminolysis metabolism may provide a new therapeutic strategy for the aggressive subgroups of ER-positive cancers or ER-negative cancers.

Choline-containing metabolites including Cho, PC, and GPC are associated with cell signaling, lipid metabolism and cell membrane synthesis and degradation [40]. In our study, Cho and PC levels were higher in the HER2-positive and luminal B subgroups of ER-positive breast cancer. However, the differences in these metabolite levels did not reach statistical significance, which may be due to the relatively lower levels of choline-containing metabolites of ER-positive cancers compared to ER-negative cancers [20, 41]. Nonetheless, the tendency of higher levels of PC and Cho in the HER2-positive and luminal B subgroups of our ER-positive cancer samples is in accordance with those from recent metabolomics studies using CNB specimens or surgical tissue which found significant correlation between choline-containing metabolites in breast cancer tissue and the aggressive subgroups of breast cancer [18, 20]. These results may be a consequence of the up-regulation of choline kinase activity, which is associated with tumor aggressiveness and drug sensitivity [34, 40, 42, 43]. Down-regulation of choline kinase has been shown to decrease cell proliferation and to increase the effect of chemotherapy in breast cancers [42, 43]. Therefore, we suggest that choline-containing metabolites may be biomarkers related to the aggressive subgroups of ER-positive cancers.

In our OPLS-DA analysis, higher levels of Leu were associated with the less aggressive groups (HER2-negative, low Ki-67, and luminal A) of ER-positive cancers, although the levels of Leu did not reach statistical significance in univariate analysis. In addition, the luminal A group showed higher levels of Ile compared to luminal B. Although little is known about the relationship between breast cancer and branched-chain amino acids (BCAA) including Leu, Ile, and valine, a recent study has reported that plasma levels of Leu and BCAA (sum of Ile, Leu, and valine levels) were significantly correlated with the level of free testosterone in premenopausal women [44]. Leu and testosterone levels in plasma have been associated with obesity and insulin resistance [45, 46], which are identified as risk factors for breast cancer [47]. Considering these findings, one possible hypothesis is that increased BCAA levels in the less aggressive subgroups of our ER-positive cancers is that a subgroup with obesity or insulin resistance may be associated with better prognosis than a subgroup without. So, higher levels of BCAA may be a marker of patient obesity or insulin resistance, not a prognostic marker. To our knowledge, this study was the first to suggest the Leu level in CNB samples as a biomarker for ER-positive cancers. Therefore,
additional studies are needed to evaluate whether BCAA can be appropriate biomarkers associated with the prognosis of ER-positive cancers.

OPLS-DA multivariate models using HR-MAS MRS data of pretreatment CNB cancer samples provided visible discrimination between the luminal A and luminal B groups, which supports the usefulness of molecular subclassification of ER-positive cancers widely used in clinical practice. The diagnostic accuracy for predicting the luminal type was higher than those for predicting the groups classified by a single factor (HER2 and Ki-67, respectively). Our results suggest that OPLS-DA multivariate analysis using HR-MAS MRS metabolic profiles of CNB samples may provide comprehensive prognostic information reflecting molecular features of ER-positive cancers. Therefore, prognostic information obtained with HR-MAS MRS metabolic profiles may help define a clinical subgroup of ER-positive cancers for which aggressive therapy such as additional cytotoxic chemotherapy should be considered over conventional treatment. In addition, the metabolites that contribute to the prediction of luminal type (Gly, PC and Leu) in univariate and OPLS-DA analyses can be more powerful targets for metabolic drugs. Based on our results, HR-MAS MRS metabolic profiles of CNB samples are thought to potentially help clinicians develop more personalized treatment protocols for ER-positive cancers.

This study had several limitations. First, we could not evaluate associations between metabolic profiles of samples and long-term outcomes of study patients, because no recurrences were observed during the follow-up period. Recently, ESR1 gene mutations have been found in 15-20% of patients with endocrine-resistant metastatic ER-positive cancers, the majority of which are treated with endocrine therapy [48, 49]. Third, there has been concern that biospecimen type (in vivo CNB sample vs. ex vivo surgical sample) may affect biomarkers or metabolic profiling. However, we did not compare HR-MAS MRS data obtained with CNB specimens with the data obtained with surgical specimens. Therefore, we cannot exclude the possibility that HR-MAS MRS metabolic profiles of the CNB specimen may not fully represent the metabolic composition of the tumors with heterogeneous histologic features, although a recent study reported that most individual proteomic biomarkers studied did not differ according to biospecimen type [29]. Fourth, we used TSP as an internal reference for metabolite quantification. Although TSP has been commonly used as a reference substance in HR-MAS MRS experiments [18-22, 24, 25, 52, 53], it can potentially bind to some proteins [54]. Therefore, we tried to compensate for this binding effect by taking the protein-bound TSP signal into account when setting up the TSP signal as our reference value for metabolite quantification. In spite of this effort, we could not rule out the possibility of unwanted errors from pathological differences between the cancer samples [55]. Thus, we used metabolite levels calculated by the relative quantification method in our comparison analysis. Finally, we used surrogate IHC measurement instead of multi-gene molecular assays for subtype classification of ER-positive cancers. Although multi-gene molecular assays were recognized as providing accurate and reproducible prognostic information, surrogate IHC-based classification was more widely applicable at a lower cost and was more readily available [8].

In conclusion, metabolic profiles of CNB samples of ER-positive breast cancers showed significant correlation with HER2, Ki-67, and luminal type. Our results indicate that the metabolic profiles of CNB samples assessed by HR-MAS MRS can be used to detect potential prognostic biomarkers as well as to understand the difference in metabolic mechanism among subtypes of ER-positive breast cancer.

### Table 3: Correlation of molecular and pathologic characteristics of 62 ER-positive breast cancers in this study

| Tumor size | HER2-negative (n=52) | HER2-positive (n=10) | Ki-67 low (n=39) | Ki-67 high (n=23) | Luminal A (n=36) | Luminal B (n=26) |
|------------|----------------------|---------------------|-----------------|-----------------|----------------|----------------|
| <2cm (n=46) | 39                   | 7                   | 32              | 14              | 29             | 17             |
| ≥ 2cm (n=16) | 13                   | 3                   | 7               | 9               | 7              | 9              |
| Lymph node metastasis | | | | | | |
| Negative (n=40) | 32                    | 8                    | 21              | 19              | 20             | 20             |
| Positive (n=22) | 20                    | 2                    | 18              | 4               | 16             | 6              |

Data present number of cancers.

Although recent studies have reported that the tumor-stroma ratio of breast cancer is associated with the prognosis [50, 51].
MATERIALS AND METHODS

Patient and sample preparation

The institutional review board of Severance Hospital, Yonsei University College of Medicine, approved this prospective study, and written informed consent was obtained from all patients. Between December 2011 and December 2013, we initially enrolled 97 patients with 100 breast lesions assessed by the Breast Imaging Reporting and Data System as final assessment categories 4c or 5 [56], and larger than 1 cm in diameter on mammography or ultrasound (US). Finally, 61 patients with 62 breast lesions fulfilled the following inclusion criteria: (a) having a breast lesion pathologically diagnosed as ER-positive cancer by CNB, (b) not pregnant at the time of diagnosis, and (c) no history of breast cancer or previous breast surgery including breast implants. All patients were treated with surgery and seven patients underwent neoadjuvant chemotherapy (NAC) prior to surgery.

For pathologic diagnosis of each patient, US-guided CNB was performed with a 14-gauge dual-action semiautomatic core biopsy needle (Stericut with coaxial guide; TSK laboratory, Tochigi, Japan) by one of four radiologists (with 7-15 years of experience in breast imaging) before treatment (surgery or NAC prior to surgery). The radiologists targeted the homogeneously solid area for biopsies of large and heterogeneous lesions. An average of six (range 5-8) tissue samples were acquired by US-guided CNB. Leaving out one core sample of each lesion, the rest of samples were taken for histopathologic diagnosis and immunohistochemical (IHC) analysis. The core sample was put in a cryogenic vial and immersed in liquid nitrogen immediately after biopsy for HR-MAS MRS. These samples were kept in a freezer (MVE Cryosystem, Chart BioMed, CA, USA) at -162°C for one to five months before the HR-MAS MRS experiment.

Pathologic analysis

For primary breast cancers, final histopathologic results of CNB and surgical specimens were reviewed to determine final diagnosis, tumor size, and molecular subtype determined by ER, progesterone receptor [PR], HER2, and Ki-67 status. Axillary lymph node status was determined by surgical histopathologic results and preoperative fine-needle aspiration biopsy results.

ER and PR positivity were defined using a cutoff value of > 1% positively stained nuclei [57]. HER2 staining using the Hercep Test TM (DAKO, Glostrup, Denmark) was interpreted as 0, 1+, 2+, or 3+ according to the guidelines of the American Society Clinical Oncology/College of American Pathologists [58]. Tumors scored as 3+ were considered HER2-positive cases whereas tumors with 0 to 1+ were regarded as negative cases. Tumors scored as 2+ required further investigation using fluorescence in situ hybridization to assess HER2 gene amplification. Ki-67 staining was scored by counting the number of cells with positively stained nuclei and was expressed as a percentage of the total number of tumor cells. Ki-67 results were classified into low (<14%) and high (≥14%) [59].

HR-MAS MRS

Frozen CNB samples were thawed in the nuclear magnetic resonance (NMR) laboratory, weighed, and placed in a HR-MAS nanoprobe® (Agilent, Walnut Creek, CA, USA). The samples (mean weight 10 mg) were cut to fit a 40- μl NMR nanotube, and they were placed in the cell with the remaining volume filled with D2O containing 2 mM trimethylsilyl propionic acid (TSP) for chemical shift referencing. HR-MAS MR spectra were acquired with an NMR spectrometer (Agilent, VNMRS 600) operating at a proton NMR frequency of 600 MHz (11.74 T). An inverse-detection type probe equipped with a single Z gradient coil was used and the temperature was set to 26°C after calibration with methanol. The spectral acquisition parameters were as follows: CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence to impose a T2 filter \{[recycle delay-90°-(τ-180°-τ) 80-acquisition] (pw90=6.0 us, τ=469.0 us}\}, spinning rate of 2 kHz, 19.231 K complex data points, 9615.4 Hz sweep width, 2.0-s acquisition time, 1.0-s relaxation delay, 1.5-s saturation time, 256 number of transients, and total acquisition time of 16 min 18 sec.

Following acquisition, the spectra were processed and analyzed using ACD software (Advanced Chemistry Development, Toronto, Ontario, Canada) followed by post-processing steps of Fourier transformation, phasing and baseline correction. TSP was calibrated to 0.00 ppm, and spectral region from 0.5 to 7.6 ppm was chosen as the final input data analysis. Signals of chemical contamination (e.g., ethanol), water, and lipids were excluded ahead of the analysis. The peak amplitude of each metabolite was measured by fitting a Voigt (e.g., Gauss+Lorentz) line-shape function. Relative metabolite quantification was carried out based on the comparison between the integrated TSP signal and the signal of interest in the sample spectrum.

Follow-up

Curative breast surgery was performed on all study patients and seven patients underwent NAC prior to surgery. Adjuvant endocrine therapy and/or chemotherapy were performed according to the pathologic characteristics of the cancers [60]. All patients were examined with mammography and US every 6 months for the first 2 years after surgery and annual mammography and US thereafter. Locoregional recurrence limited to the ipsilateral breast or chest wall and/or regional lymph node recurrence (axillary, infraclavicular, or supraclavicular lymph nodes), contralateral breast cancer, and distant metastasis to other body organs were regarded as breast cancer recurrence) [61].
Data and statistical analysis

Pathologic characteristics of the included tumors were collected from a review of patient medical records, and are listed in Table 3. Tumor size was determined as the maximum diameter of invasive tumor on final pathologic results (n=55). However, tumor size measured with US was used for patients treated with neoadjuvant chemotherapy (n=7). For statistical analysis, tumors were grouped by status of HER2, and Ki-67, and St Gallen surrogate molecular subtype (luminal A or luminal B) [20, 22]. The Kolmogorov–Smirnov test was used to check for normal distribution of relative quantification levels of metabolites of CNB samples. The relative quantification levels of the metabolites (alanine [Ala], creatine [Cr], free choline [Cho], phosphocholine [PC], glycerophosphocholine [GPC], glutamine [Gln], glutamate [Glu], leucine [Leu], isoleucine [Ile], myo-inositol [m-Ins], taurine [Tau], serine [Ser] and glycine [Gly]; Supplementary Table 1) were compared according to the tumor groups using the Mann-Whitney test. Statistical analysis was performed with SAS for Windows, version 9.0 (SAS Institute, Cary, NC, USA). A P value of less than 0.0167 (Bonferroni corrected P=0.05/3) was considered to indicate a significant difference between groups.

For multivariate analysis, Matlab (MathWorks, Natick, MA), SIMCA-P+ 12.0 (Umetrics, Sweden), and Excel (Microsoft, Seattle, WA) programs were used. Orthogonal projections to latent structure discriminant analysis (OPLS-DA) were conducted to separate the tumor groups with metabolic profiles of CNB samples by building the statistical models. The statistical relevance was verified using “Y-scrambling” validation, and the resulting R² and Q² values were calculated. The R² value represents the “goodness of fit” which reflects how close the calculated data are to the original data. By repeated fitting, the R² value can be artificially increased, leading to a decrease in the Q² value, the predictability. Therefore, statistical soundness can be checked by randomly permutating the group designation of the original data and seeing if the calculation can correctly differentiate the groups with this deliberately generated model. The model was validated by prediction of unknown samples using a leave-one-out method [62]. An a priori cut-off value of 0.5 was applied to evaluate the prediction results [63]. Signals contributing to group discrimination were detected by an S-plot and the corresponding spectral data were extracted from Chenomx (Spectral database; Edmonton, Alberta, Canada) software and an in-house data repository. Any signals related to contamination (e.g. ethanol and methanol) were removed from the statistical analysis of spectral data.

Abbreviations

ER, estrogen receptor; HR-MAS MRS, high-resolution magic angle spinning magnetic resonance spectroscopy; CNB, core needle biopsy; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; OPLS-DA, orthogonal projections to latent structure discriminant analysis; US, ultrasound; NAC, neoadjuvant chemotherapy; IHC, immunohistochemical; NMR, nuclear magnetic resonance; TSP, trimethylsilyl propionic acid; Cr, creatine; Ala, alanine; Cho, free choline; PC, phosphocholine; GPC, glycerophosphocholine; Glu, glutamine; Glu, glutamate; Tau, leucine; Ile, isoleucine; m-Ins, myo-inositol; Tau, taurine; Ser, serine; Gly, glycine; GLDC, glycine decarboxylase; BCAA, branched-chain amino acids.

Author contributions

Min Jung Kim designed and performed the experiments, analyzed and interpreted data. Ji Soo Choi analyzed and interpreted the data and wrote the paper. Dahye Yoon, Ja Seoug Koo, Siwon Kim, Vivian Youngjean Park and Jung Hyun Yoon performed experiments. Min Jung Kim, Eun-Kyung Kim, Hee Jung Moon, and Suhkmann Kim revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

FUNDING

This study was supported by faculty research grant of Yonsei University College of Medicine for (6-2015-0050) and the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT& Future Planning, Republic of Korea (preparation of the manuscript; grant 2013R1A1A3013165). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349:1793-1802.
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-1717.
3. Jordan VC, O’Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007; 25:5815-5824.
4. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359:2131-2139.

5. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010; 4:192-208.

6. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006; 7:96.

7. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies F, Fauron C, He X, Hu Z, Quackenbush JF, Stjileman IJ, Palazzo J, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27:1160-1167.

8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22:1736-1747.

9. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008; 14:5158-5165.

10. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008; 10:R65.

11. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 2012; 19:39-53.

12. Denkert C, Bucher E, Hilvo M, Salek R, Oresic M, Griffin J, Brockmoller S, Klauschen F, Loibl S, Barupal DK, Budezies J, Iliin K, Nekljudova V, et al. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 2012; 4:37.

13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.

14. Fiehn O. Metabolomics--the link between genotypes and phenotypes. Plant Mol Biol. 2002; 48:155-171.

15. Aboud OA, Weiss RH. New opportunities from the cancer metabolome. Clin Chem. 2013; 59:138-146.

16. Oakman C, Tenori L, Biganzoli L, Santarpia L, Cappadona S, Luchinat C, Di Leo A. Uncovering the metabolomic fingerprint of breast cancer. Int J Biochem Cell Biol. 2011; 43:1010-1020.

17. German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics. 2005; 1:3-9.

18. Cao MD, Lamichhane S, Lundgren S, Bofin A, Fjosne H, Giskeodegard GF, Bathe TF. Metabolic characterization of triple negative breast cancer. BMC Cancer. 2014; 14:941.

19. Cao MD, Sitter B, Bathe TF, Bofin A, Lomning PE, Lundgren S, Gribbestad IS. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed. 2012; 25:369-378.

20. Choi JS, Baek HM, Kim S, Kim MJ, Youk JH, Moon HJ, Kim EM, Han KH, Kim DH, Kim SI, Koo JS. HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors. PLoS One. 2012; 7:e51712.

21. Choi JS, Baek HM, Kim S, Kim MJ, Youk JH, Moon HJ, Kim EM, Nam YK. Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapy. PLoS One. 2013; 8:e83866.

22. Sitter B, Bathe TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, Gribbestad IS. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010; 23:424-431.

23. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002; 15:327-337.

24. Li M, Song Y, Cho N, Chang JM, Koo HR, Yi A, Kim H, Park S, Moon WK. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS One. 2011; 6:e25563.

25. Borgan E, Sitter B, Lingjaerde OC, Johnsen H, Lundgren S, Bathe TF, Sorlie T, Borresen-Dale AL, Gribbestad IS. Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer. 2010; 10:628.

26. Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, Ricks-Santi LJ, Dasi S, Day A, Blackman KW, Frederick W, Copeland RL Jr, Gabrielson E, Dewitty RL Jr. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics Proteomics. 2014; 11:279-294.

27. Giskeodegard GF, Grinde OD, Chandak BN, Bofin A, Dahl S, Gribbestad IS, Bathe TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res. 2010; 9:972-979.

28. Bassett LW, Mahoney MC, Apple SK. Interventional breast imaging: current procedures and assessing for concordance with pathology. Radiol Clin North Am. 2007; 45:881-894, vii.
29. Meric-Bernstam F, Akgakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, et al. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014; 20:3870-3883.

30. Pinhel IF, Macneill FA, Hills MJ, Salter J, Daret S, A'Hern R, Nerukar A, Osin P, Smith IE, Dowsett M. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res. 2010; 12:R76.

31. Cho N. Molecular subtypes and imaging phenotypes of breast cancer. Ultrasonography. 2016; 35:281-829.

32. Nahta R, Shahaya S, Ozbay T, Rowe DL. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmagenomics Person Med. 2009; 7:263-274.

33. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn. 2006; 6:821-829.

34. Granata A, Nicoletti R, Tinaglia V, De Cecco L, Pisanu ME, Ricci A, Podo F, Canevari S, Iorio E, Bagnoli M, Mezzanzanica D. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer. 2014; 110:330-340.

35. Giskeodegard GF, Lundgren S, Sitter B, Fjosne HE, Postma ME, Gribbestad IS, Bathen TF. Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers. NMR Biomed. 2012; 25:1271-1279.

36. Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, Tollenaar RA, Mesker WE. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat. 2013; 139:371-379.

37. De Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbeej V, Sotiriou C, Larsimont D, Piccart-Gebhart M, Paesmans M. Ki-67 as prognostic marker in hormone-resistant metastatic breast cancer. Nat Genet. 2013; 45:1446-1451.

38. Rose DP, Kominou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004; 5:153-165.

39. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012; 279:2610-2623.

40. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013; 45:1446-1451.

41. Shin HI, Baek HM, Cha JH, Kim HH. Evaluation of breast cancer using proton MR spectroscopy: total choline peak integral and signal-to-noise ratio as prognostic indicators. AJR Am J Roentgenol. 2012; 198:W488-W497.

42. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 2007; 67:11284-11290.

43. Shah T, Wildes F, Penet MF, Winnard PT Jr, Glunde K, Artemov D, Ackerstaff E, GimI B, Kakkad S, Raman V, Bhujwalla ZM. Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed. 2010; 23:633-642.

44. Nagata C, Wada K, Tsuji M, Hayashi M, Takeda N, Yasuda K. Plasma amino acid profiles are associated with biomarkers of breast cancer risk in premenopausal Japanese women. Cancer Causes Control. 2014; 25:143-149.

45. Batch BC, Shah SH, Newgard CB, Turer CB, Haynes C, Bain JR, Muehlbauer M, Patel MJ, Stevens RD, Appel LJ, Newby LK, Svetkey LP. Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. Metabolism. 2013; 62:961-969.

46. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012; 279:2610-2623.

47. Rose DP, Kominou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004; 5:153-165.

48. Moran J, Hernandez-Pech X, Merchant-Larios H, Pasantes-Morales H. Release of taurine in apoptotic cerebellar granule neurons in culture. Pflugers Arch. 2000; 439:271-277.

49. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013; 45:1446-1451.

50. de Kruifj EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat. 2011; 125:687-696.

51. Romero Alvira D, Villalba Martin MP, Bueno Gonzalez J. [The role of pro-oxidation and antioxidation in the etiology of arterial hypertension]. [Article in Spanish]. Med Clin (Bare). 1991; 97:542-551.

52. Park VY, Yoon D, Koo JS, Kim EK, Kim SI, Choi JS, Park S, Park HS, Kim S, Kim MJ. Intratumoral agreement of high-resolution magic angle spinning magnetic resonance spectroscopic profiles in the metabolic characterization of breast cancer. Medicine (Baltimore). 2016; 95:e3398.

53. Yoon H, Yoon D, Yun M, Choi JS, Park VY, Kim EK, Jeong J, Koo JS, Yoon JH, Moon HJ, Kim S, Kim MJ. Metabolomics of breast cancer using high-resolution...
magic angle spinning magnetic resonance spectroscopy: correlations with 18F-FDG positron emission tomography-computed tomography, dynamic contrast-enhanced and diffusion-weighted imaging MRI. PLoS One. 2016; 11:e0159949.

54. Kriat M, Confort-Gouny S, Vion-Dury J, Sciaky M, Viout P, Cozzone PJ. Quantitation of metabolites in human blood serum by proton magnetic resonance spectroscopy. A comparative study of the use of formate and TSP as concentration standards. NMR Biomed. 1992; 5:179-184.

55. Dou W, Wang S, Constans JM, Li S. Automatic Data Processing to Relative Quantitative Analysis of 1H MR Spectroscopy of Brain. 2009 3rd International Conference on Bioinformatics and Biomedical Engineering: IEEE; 2009;1-4.

56. D’Orsi C, Sickles E, Mendelson E, Morris E. 2013 ACR BI-RADS Atlas: breast imaging reporting and data system. 2014.

57. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28:2784-2795.

58. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25:118-145.

59. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101:736-750.

60. Gradishar W, Salerno KE. NCCN guidelines update: breast cancer. J Natl Compr Canc Netw. 2016; 14:641-644.

61. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KL, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007; 25:2127-2132.

62. Wen H, Yoo SS, Kang J, Kim HG, Park JS, Jeong S, Lee JI, Kwon HN, Kang S, Lee DH. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol. 2010; 52:228-233.

63. Brindle JT, Antii H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002; 8:1439-1444.